Admin

    BCG Vaccine for Covid-19 in Health Care Workers

    Evaluation of BCG-Denmark vaccine’s effect on Covid-19 risk among healthcare workers Study design International, double-blind, placebo-controlled trial Population Interventions Primary outcome: Symptomatic Covid-19 and severe Covid-19 by 6 months Secondary outcomes Hazard ratio for any Covid-19 episode: 1.23 (95% CI, 0.96 to 1.59) Safety outcomes Adverse Events BCG Group Placebo Group Serious 20 9 Potential…

    Read More

      Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

      Study design RCT Population Interventions Primary outcome: % Metastasis at 15 years Secondary outcomes Outcome Active-monitoring Prostatectomy Radiotherapy Metastases 51 26 27 Long-term ADT initiation 69 40 42 Clinical progression 141 58 60 Potential Issues and Biases Since the trial’s inception, treatments and diagnostic methods have evolved. Investigators were not using contemporary multiparametric MRI or…

      Read More

        Helping People Stop Smoking

        Cigarette Smoking & Health ImpactCigarette smoking remains the leading preventable cause of illness and death in the United States, with one in eight adults smoking. Most smokers are aware of health risks but struggle to quit due to nicotine dependence. In 2018, 55% of smokers attempted to quit, but only 7.5% succeeded. FDA Regulation &…

        Read More

          Once-Weekly Basal Insulin vs. Degludec in T1DM

          Basal Insulin Fc (BIF) vs Degludec in Type 1 Diabetes Patients Using Multiple Daily Injections Study design: Phase 2, randomized, parallel, open-label study Population: 265 patients with type 1 diabetes (T1D) using multiple daily injections Interventions Primary outcome: HbA1c change from baseline to week 26 Secondary/ Safety outcomes Safety Outcomes BIF once weekly HbA1c change…

          Read More

            Fluvoxamine with Inhaled Budesonide for COVID-19

            Does the combination of fluvoxamine and inhaled budesonide increase treatment effects in a highly vaccinated population with early COVID-19? Study design Randomized, placebo-controlled, adaptive platform trial. Population Interventions Primary outcome: Composite of emergency setting retention for COVID-19 for more than 6 hours, hospitalization, and/or suspected complications due to clinical progression of COVID-19 within 28 days…

            Read More

              Treat-to-Target LDL-C vs. High-Intensity Statin Therapy in CAD

              Is treat-to-target LDL-C strategy noninferior to high-intensity statin therapy for long-term clinical outcomes in patients with coronary artery disease? Study design: Randomized, multicenter, noninferiority trial Population Interventions Primary outcome: 3-year composite of death, myocardial infarction, stroke, or coronary revascularization Secondary outcomes Safety outcomes or Adverse Events Safety Outcomes Treat-to-Target Group (%) High-Intensity Statin Group (%)…

              Read More

                Ultrasonography vs. CXR for Pneumothorax Detection

                How does the diagnostic accuracy of chest ultrasonography (CUS) compare to chest X-ray (CXR) for detecting pneumothorax in trauma patients in the emergency department (ED)? Study design: Systematic review and meta-analysis of 13 prospective, paired comparative accuracy studies Population Interventions Primary outcome: Sensitivity and specificity of CUS and CXR for pneumothorax detection Conclusion The diagnostic…

                Read More

                  TRANSFORM-HF

                  Does torsemide reduce all-cause mortality compared with furosemide in patients with heart failure following hospitalization? Study design: Open-label, pragmatic randomized trial Population Interventions Primary outcome: All-cause mortality in a time-to-event analysis Conclusion Among patients discharged after hospitalization for heart failure, torsemide compared with furosemide did not result in a significant difference in all-cause mortality over…

                  Read More

                    SURPASS-I

                    Efficacy and safety of tirzepatide in people with obesity Study design: Phase 3 double-blind, randomized, controlled trial Population Interventions Primary outcome: Percentage change in weight from baseline and a weight reduction of 5% or more Safety outcomes or Adverse Events Adverse events in 78.9% to 81.8% of participants treated with tirzepatide, compared to 72.0% in…

                    Read More

                      Hydroxychloroquine for COVID (France)

                      Early treatment with hydroxychloroquine and azithromycin for COVID-19 patients: a retrospective analysis in Marseille, France Study design: Retrospective analysis Population Interventions Primary outcome: Transfer to ICU or death, hospitalization ≥10 days, and duration of viral shedding Safety outcomes or Adverse Events QTc prolongation (>60 ms) in 25 patients (0.67%); treatment cessation in 12 cases including…

                      Read More